These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 19145485)

  • 1. Immunogenic cell death modalities and their impact on cancer treatment.
    Kepp O; Tesniere A; Schlemmer F; Michaud M; Senovilla L; Zitvogel L; Kroemer G
    Apoptosis; 2009 Apr; 14(4):364-75. PubMed ID: 19145485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunogenicity of tumor cell death.
    Kepp O; Tesniere A; Zitvogel L; Kroemer G
    Curr Opin Oncol; 2009 Jan; 21(1):71-6. PubMed ID: 19125021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characteristics of immunogenic cancer cell death.
    Tesniere A; Panaretakis T; Kepp O; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
    Cell Death Differ; 2008 Jan; 15(1):3-12. PubMed ID: 18007663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic cancer cell death: a key-lock paradigm.
    Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
    Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor stress, cell death and the ensuing immune response.
    Ullrich E; Bonmort M; Mignot G; Kroemer G; Zitvogel L
    Cell Death Differ; 2008 Jan; 15(1):21-8. PubMed ID: 17992190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ecto-calreticulin in immunogenic chemotherapy.
    Obeid M; Tesniere A; Panaretakis T; Tufi R; Joza N; van Endert P; Ghiringhelli F; Apetoh L; Chaput N; Flament C; Ullrich E; de Botton S; Zitvogel L; Kroemer G
    Immunol Rev; 2007 Dec; 220():22-34. PubMed ID: 17979837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
    Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
    Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenic death of colon cancer cells treated with oxaliplatin.
    Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
    Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Death by design: apoptosis, necrosis and autophagy.
    Edinger AL; Thompson CB
    Curr Opin Cell Biol; 2004 Dec; 16(6):663-9. PubMed ID: 15530778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunological aspects of anticancer chemotherapy].
    Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
    Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
    Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
    Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The redox protein HMGB1 regulates cell death and survival in cancer treatment.
    Tang D; Loze MT; Zeh HJ; Kang R
    Autophagy; 2010 Nov; 6(8):1181-3. PubMed ID: 20861675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
    Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
    J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity.
    Brusa D; Garetto S; Chiorino G; Scatolini M; Migliore E; Camussi G; Matera L
    Vaccine; 2008 Nov; 26(50):6422-32. PubMed ID: 18848858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Witch hunt against tumor cells enhanced by dendritic cells.
    Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
    Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell death and autophagy: cytokines, drugs, and nutritional factors.
    Bursch W; Karwan A; Mayer M; Dornetshuber J; Fröhwein U; Schulte-Hermann R; Fazi B; Di Sano F; Piredda L; Piacentini M; Petrovski G; Fésüs L; Gerner C
    Toxicology; 2008 Dec; 254(3):147-57. PubMed ID: 18694801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.
    van der Most RG; Currie AJ; Robinson BW; Lake RA
    Cell Death Differ; 2008 Jan; 15(1):13-20. PubMed ID: 18007666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death.
    Martins I; Michaud M; Sukkurwala AQ; Adjemian S; Ma Y; Shen S; Kepp O; Menger L; Vacchelli E; Galluzzi L; Zitvogel L; Kroemer G
    Autophagy; 2012 Mar; 8(3):413-5. PubMed ID: 22361584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response against dying tumor cells.
    Zitvogel L; Casares N; Péquignot MO; Chaput N; Albert ML; Kroemer G
    Adv Immunol; 2004; 84():131-79. PubMed ID: 15246252
    [No Abstract]   [Full Text] [Related]  

  • 20. Capitalizing on the immunogenicity of dying tumor cells.
    Fonseca C; Dranoff G
    Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.